The adipokine/ceramide axis: Key aspects of insulin sensitization

Biochimie

Volumn 96, Issue 1, 2014, Pages 130-139

  Xia, Jonathan Y ^a   Morley, Thomas S ^a   Scherer, Philipp E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Ceramide target tissues; Ceramides; Insulin sensitivity; Plasma ceramide levels; Sphingolipids

Indexed keywords

ACYL COENZYME A; ADIPOCYTOKINE; ADIPONECTIN; CERAMIDE; CERAMIDE 1 PHOSPHATE; DIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR 21; FINGOLIMOD; FUMONISIN; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNSATURATED FATTY ACID;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CATABOLISM; CELL CYCLE PROGRESSION; CELL SURVIVAL; DISEASE COURSE; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY LIVER; HEART INJURY; HEART MUSCLE CONTRACTILITY; HUMAN; INFECTION CONTROL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SENSITIZATION; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER CELL; LIVER DYSFUNCTION; MACROPHAGE; METABOLIC DISORDER; MITOCHONDRIAL MEMBRANE POTENTIAL; MUCOSAL IMMUNITY; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; STEADY STATE; TISSUE REPAIR;

CERAMIDE TARGET TISSUES; CERAMIDES; INSULIN SENSITIVITY; PLASMA CERAMIDE LEVELS; SPHINGOLIPIDS;

ADIPOKINES; ANIMALS; CERAMIDES; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; MACROPHAGES; METABOLIC DISEASES; ORGAN SPECIFICITY; SPHINGOLIPIDS; SPHINGOSINE;

EID: 84890467958     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2013.08.013     Document Type: Review

References (104)

1. W.L. Holland, and S.A. Summers Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism Endocr. Rev. 29 2008 381 402
2. 1H-spectroscopic study in Zucker diabetic fatty rats Diabetes 52 2003 138 144
3. K.F. Petersen, and G.I. Shulman Etiology of insulin resistance Am. J. Med. 119 2006 S10 S16
4. F.R. Jornayvaz, and G.I. Shulman Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance Cell Metab. 15 2012 574 584
5. W.L. Holland, J.T. Brozinick, L.P. Wang, E.D. Hawkins, K.M. Sargent, Y. Liu, K. Narra, K.L. Hoehn, T.A. Knotts, A. Siesky, D.H. Nelson, S.K. Karathanasis, G.K. Fontenot, M.J. Birnbaum, and S.A. Summers Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance Cell Metab. 5 2007 167 179
6. A. Jaworowska, T. Blackham, I.G. Davies, and L. Stevenson Nutritional challenges and health implications of takeaway and fast food Nutr. Rev. 71 2013 310 318
7. W.L. Holland, T.A. Knotts, J.A. Chavez, L.P. Wang, K.L. Hoehn, and S.A. Summers Lipid mediators of insulin resistance Nutr. Rev. 65 2007 S39 S46
8. C.R. Gault, L.M. Obeid, and Y.A. Hannun An overview of sphingolipid metabolism: from synthesis to breakdown Adv. Exp. Med. Biol. 688 2010 1 23
9. G. Frangioudakis, J. Garrard, K. Raddatz, J.L. Nadler, T.W. Mitchell, and C. Schmitz-Peiffer Saturated- and n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors Endocrinology 151 2010 4187 4196
10. Y.T. Chang, J. Choi, S. Ding, E.E. Prieschl, T. Baumruker, J.M. Lee, S.K. Chung, and P.G. Schultz The synthesis and biological characterization of a ceramide library J. Am. Chem. Soc. 124 2002 1856 1857
11. K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614
12. C.J. Clarke, C.F. Snook, M. Tani, N. Matmati, N. Marchesini, and Y.A. Hannun The extended family of neutral sphingomyelinases Biochemistry 45 2006 11247 11256
13. C.J. Clarke, and Y.A. Hannun Neutral sphingomyelinases and nSMase2: bridging the gaps Biochim. Biophys. Acta 1758 2006 1893 1901
14. J.P. Kirwan Plasma ceramides target skeletal muscle in type 2 diabetes Diabetes 62 2013 352 354
15. J.M. Haus, S.R. Kashyap, T. Kasumov, R. Zhang, K.R. Kelly, R.A. Defronzo, and J.P. Kirwan Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance Diabetes 58 2009 337 343
16. J.T. Brozinick, E. Hawkins, H. Hoang Bui, M.S. Kuo, B. Tan, P. Kievit, and K. Grove Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet Int. J. Obes. (Lond.) 2012
17. P. Wiesner, K. Leidl, A. Boettcher, G. Schmitz, and G. Liebisch Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry J. Lipid Res. 50 2009 574 585
18. G. Wang, M. Dinkins, Q. He, G. Zhu, C. Poirier, A. Campbell, M. Mayer-Proschel, and E. Bieberich Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD) J. Biol. Chem. 287 2012 21384 21395
19. J. Boon, A.J. Hoy, R. Stark, R.D. Brown, R.C. Meex, D.C. Henstridge, S. Schenk, P.J. Meikle, J.F. Horowitz, B.A. Kingwell, C.R. Bruce, and M.J. Watt Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance Diabetes 62 2013 401 410
20. X. Lopez, A.B. Goldfine, W.L. Holland, R. Gordillo, and P.E. Scherer Plasma ceramides are elevated in female children and adolescents with type 2 diabetes J. Pediatr. Endocrinol. Metab. 2013 1 4
21. V.D. de Mello, M. Lankinen, U. Schwab, M. Kolehmainen, S. Lehto, T. Seppanen-Laakso, M. Oresic, L. Pulkkinen, M. Uusitupa, and A.T. Erkkila Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease Diabetologia 52 2009 2612 2615
22. C.K. Huang, R. Goel, P.C. Chang, C.H. Lo, and A. Shabbir Single-incision transumbilical (SITU) surgery after SITU laparoscopic Roux-en-Y gastric bypass J. Laparoendosc. Adv. Surg. Tech. Part A 22 2012 764 767
23. K.E. Wellen, and G.S. Hotamisligil Obesity-induced inflammatory changes in adipose tissue J. Clin. Invest. 112 2003 1785 1788
24. H. Xu, G.T. Barnes, Q. Yang, G. Tan, D. Yang, C.J. Chou, J. Sole, A. Nichols, J.S. Ross, L.A. Tartaglia, and H. Chen Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J. Clin. Invest. 112 2003 1821 1830
25. A.H. Berg, and P.E. Scherer Adipose tissue, inflammation, and cardiovascular disease Circ. Res. 96 2005 939 949
26. I.W. Asterholm, J. McDonald, P.G. Blanchard, M. Sinha, Q. Xiao, J. Mistry, J.M. Rutkowski, Y. Deshaies, R.A. Brekken, and P.E. Scherer Lack of «immunological fitness» during fasting in metabolically challenged animals J. Lipid. Res. 53 2012 1254 1267
27. C.N. Lumeng, S.M. Deyoung, J.L. Bodzin, and A.R. Saltiel Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity Diabetes 56 2007 16 23
28. Z.Q. Chang, S.Y. Lee, H.J. Kim, J.R. Kim, S.J. Kim, I.K. Hong, B.C. Oh, C.S. Choi, I.J. Goldberg, and T.S. Park Endotoxin activates de novo sphingolipid biosynthesis via nuclear factor kappa B-mediated upregulation of Sptlc2 Prostaglandins Other Lipid Mediat. 94 2011 44 52
29. J.D. Schilling, H.M. Machkovech, L. He, R. Sidhu, H. Fujiwara, K. Weber, D.S. Ory, and J.E. Schaffer Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages J. Biol. Chem. 288 2013 2923 2932
30. M. Levi, M.M. Meijler, A. Gomez-Munoz, and T. Zor Distinct receptor-mediated activities in macrophages for natural ceramide-1-phosphate (C1P) and for phospho-ceramide analogue-1 (PCERA-1) Mol. Cell. Endocrinol. 314 2010 248 255
31. M. Ojaniemi, V. Glumoff, K. Harju, M. Liljeroos, K. Vuori, and M. Hallman Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages Eur. J. Immunol. 33 2003 597 605
32. M.P. Fallah, R.L. Chelvarajan, B.A. Garvy, and S. Bondada Role of phosphoinositide 3-kinase-Akt signaling pathway in the age-related cytokine dysregulation in splenic macrophages stimulated via TLR-2 or TLR-4 receptors Mech. Ageing Dev. 132 2011 274 286
33. A. Gomez-Munoz, J.Y. Kong, B. Salh, and U.P. Steinbrecher Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages J. Lipid Res. 45 2004 99 105
34. P. Gangoiti, M.H. Granado, S.W. Wang, J.Y. Kong, U.P. Steinbrecher, and A. Gomez-Munoz Ceramide 1-phosphate stimulates macrophage proliferation through activation of the PI3-kinase/PKB, JNK and ERK1/2 pathways Cell Signal 20 2008 726 736
35. M.M. Monick, R.K. Mallampalli, A.B. Carter, D.M. Flaherty, D. McCoy, P.K. Robeff, M.W. Peterson, and G.W. Hunninghake Ceramide regulates lipopolysaccharide-induced phosphatidylinositol 3-kinase and Akt activity in human alveolar macrophages J. Immunol. 167 2001 5977 5985
36. H. Rosen, P.J. Gonzalez-Cabrera, M.G. Sanna, and S. Brown Sphingosine 1-phosphate receptor signaling Annu. Rev. Biochem. 78 2009 743 768
37. C.T. Murphy, L.J. Hall, G. Hurley, A. Quinlan, J. MacSharry, F. Shanahan, K. Nally, and S. Melgar The sphingosine-1-phosphate analogue FTY720 impairs mucosal immunity and clearance of the enteric pathogen Citrobacter rodentium Infect. Immun. 80 2012 2712 2723
38. J.E. Hughes, S. Srinivasan, K.R. Lynch, R.L. Proia, P. Ferdek, and C.C. Hedrick Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages Circ. Res. 102 2008 950 958
39. P. Keul, S. Lucke, K. von Wnuck Lipinski, C. Bode, M. Graler, G. Heusch, and B. Levkau Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis Circ. Res. 108 2011 314 323
40. F. Wang, Y. Okamoto, I. Inoki, K. Yoshioka, W. Du, X. Qi, N. Takuwa, K. Gonda, Y. Yamamoto, R. Ohkawa, T. Nishiuchi, N. Sugimoto, Y. Yatomi, K. Mitsumori, M. Asano, M. Kinoshita, and Y. Takuwa Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice J. Clin. Invest. 120 2010 3979 3995
41. J.R. Nofer, M. Bot, M. Brodde, P.J. Taylor, P. Salm, V. Brinkmann, T. van Berkel, G. Assmann, and E.A. Biessen FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice Circulation 115 2007 501 508
42. M.L. Allende, M. Bektas, B.G. Lee, E. Bonifacino, J. Kang, G. Tuymetova, W. Chen, J.D. Saba, and R.L. Proia Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking J. Biol. Chem. 286 2011 7348 7358
43. C.H. Kim, and Z.M. Younossi Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome Cleve. Clin. J. Med. 75 2008 721 728
44. A. Wieckowska, A.J. McCullough, and A.E. Feldstein Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future Hepatology 46 2007 582 589
45. A.J. McCullough Pathophysiology of nonalcoholic steatohepatitis J. Clin. Gastroenterol. 40 Suppl. 1 2006 S17 S29
46. C.L. Gentile, and M.J. Pagliassotti The role of fatty acids in the development and progression of nonalcoholic fatty liver disease J. Nutr. Biochem. 19 2008 567 576
47. C.P. Day, and O.F. James Steatohepatitis: a tale of two «hits»? Gastroenterology 114 1998 842 845
48. M. Shimabukuro, Y.T. Zhou, M. Levi, and R.H. Unger Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes Proc. Natl. Acad. Sci. U S A 95 1998 2498 2502
49. T. Yamazaki, E. Sasaki, C. Kakinuma, T. Yano, S. Miura, and O. Ezaki Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1 J. Biol. Chem. 280 2005 21506 21514
50. J.C. Cohen, J.D. Horton, and H.H. Hobbs Human fatty liver disease: old questions and new insights Science 332 2011 1519 1523
51. M. Pagadala, T. Kasumov, A.J. McCullough, N.N. Zein, and J.P. Kirwan Role of ceramides in nonalcoholic fatty liver disease Trends Endocrinol. Metab. 23 2012 365 371
52. M. Nikolova-Karakashian, A. Karakashian, and K. Rutkute Role of neutral sphingomyelinases in aging and inflammation Subcell. Biochem. 49 2008 469 486
53. R.A. Memon, W.M. Holleran, A.H. Moser, T. Seki, Y. Uchida, J. Fuller, J.K. Shigenaga, C. Grunfeld, and K.R. Feingold Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin Arterioscler. Thromb. Vasc. Biol. 18 1998 1257 1265
54. H. Shi, M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J.S. Flier TLR4 links innate immunity and fatty acid-induced insulin resistance J. Clin. Invest. 116 2006 3015 3025
55. J.Y. Lee, J. Ye, Z. Gao, H.S. Youn, W.H. Lee, L. Zhao, N. Sizemore, and D.H. Hwang Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids J. Biol. Chem. 278 2003 37041 37051
56. J.Y. Lee, K.H. Sohn, S.H. Rhee, and D. Hwang Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4 J. Biol. Chem. 276 2001 16683 16689
57. Y. Wei, D. Wang, F. Topczewski, and M.J. Pagliassotti Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells Am. J. Physiol. Endocrinol. Metab. 291 2006 E275 E281
58. W.L. Holland, B.T. Bikman, L.P. Wang, G. Yuguang, K.M. Sargent, S. Bulchand, T.A. Knotts, G. Shui, D.J. Clegg, M.R. Wenk, M.J. Pagliassotti, P.E. Scherer, and S.A. Summers Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice J. Clin. Invest. 121 2011 1858 1870
59. I. Ichi, K. Nakahara, K. Fujii, C. Iida, Y. Miyashita, and S. Kojo Increase of ceramide in the liver and plasma after carbon tetrachloride intoxication in the rat J. Nutr. Sci. Vitaminol. (Tokyo) 53 2007 53 56
60. L. Yetukuri, M. Katajamaa, G. Medina-Gomez, T. Seppanen-Laakso, A. Vidal-Puig, and M. Oresic Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis BMC Syst. Biol. 1 2007 12
61. H. Malhi, and G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin. Liver Dis. 28 2008 360 369
62. S.S. Choi, and A.M. Diehl Hepatic triglyceride synthesis and nonalcoholic fatty liver disease Curr. Opin. Lipidol. 19 2008 295 300
63. P.E. Scherer, S. Williams, M. Fogliano, G. Baldini, and H.F. Lodish A novel serum protein similar to C1q, produced exclusively in adipocytes J. Biol. Chem. 270 1995 26746 26749
64. A.T. Turer, and P.E. Scherer Adiponectin: mechanistic insights and clinical implications Diabetologia 55 2012 2319 2326
65. T. Yamauchi, J. Kamon, Y. Minokoshi, Y. Ito, H. Waki, S. Uchida, S. Yamashita, M. Noda, S. Kita, K. Ueki, K. Eto, Y. Akanuma, P. Froguel, F. Foufelle, P. Ferre, D. Carling, S. Kimura, R. Nagai, B.B. Kahn, and T. Kadowaki Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat. Med. 8 2002 1288 1295
66. A.H. Berg, T. Combs, X. Du, M. Brownlee, and P.E. Scherer The adipocyte-secreted protein Acrp30 enhances hepatic insulin action Nat. Med. 7 2001 947 953
67. T.P. Combs, A.H. Berg, S. Obici, P.E. Scherer, and L. Rossetti Endogenous glucose production is inhibited by the adipose-derived protein Acrp30 J. Clin. Invest. 108 2001 1875 1881
68. W.L. Holland, R.A. Miller, Z.V. Wang, K. Sun, B.M. Barth, H.H. Bui, K.E. Davis, B.T. Bikman, N. Halberg, J.M. Rutkowski, M.R. Wade, V.M. Tenorio, M.S. Kuo, J.T. Brozinick, B.B. Zhang, M.J. Birnbaum, S.A. Summers, and P.E. Scherer Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin Nat. Med. 17 2011 55 63
69. H. Ma, V. Gomez, L. Lu, X. Yang, X. Wu, and S.Y. Xiao Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease J. Gastroenterol. Hepatol. 24 2009 233 237
70. N. Halberg, T.D. Schraw, Z.V. Wang, J.Y. Kim, J. Yi, M.P. Hamilton, K. Luby-Phelps, and P.E. Scherer Systemic fate of the adipocyte-derived factor adiponectin Diabetes 2009
71. H. Zhou, S.A. Summers, M.J. Birnbaum, and R.N. Pittman Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis J. Biol. Chem. 273 1998 16568 16575
72. S.A. Summers, L.A. Garza, H. Zhou, and M.J. Birnbaum Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide Mol. Cell. Biol. 18 1998 5457 5464
73. R.F. Schwabe, and D.A. Brenner Mechanisms of liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways Am. J. Physiol. Gastrointest. Liver Physiol. 290 2006 G583 G589
74. S.A. Summers Ceramides in insulin resistance and lipotoxicity Prog. Lipid Res. 45 2006 42 72
75. P.E. Scherer Adipose tissue: from lipid storage compartment to endocrine organ Diabetes 55 2006 1537 1545
76. L. Laviola, S. Perrini, A. Cignarelli, and F. Giorgino Insulin signalling in human adipose tissue Arch. Physiol. Biochem. 112 2006 82 88
77. B.M. Spiegelman, and G.S. Hotamisligil Through thick and thin: wasting, obesity, and TNFa Cell 73 1993 625 627
78. G.S. Hotamisligil, and B.M. Spiegelman Tumor necrosis factor alpha: a key component of the obesity-diabetes link Diabetes 43 1994 1271 1278
79. S.D. Long, and P.H. Pekala Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes Biochem. J. 319 Pt 1 1996 179 184
80. S. Tagami, J. Inokuchi Ji, K. Kabayama, H. Yoshimura, F. Kitamura, S. Uemura, C. Ogawa, A. Ishii, M. Saito, Y. Ohtsuka, S. Sakaue, and Y. Igarashi Ganglioside GM3 participates in the pathological conditions of insulin resistance J. Biol. Chem. 277 2002 3085 3092
81. M. Kolak, J. Westerbacka, V.R. Velagapudi, D. Wagsater, L. Yetukuri, J. Makkonen, A. Rissanen, A.M. Hakkinen, M. Lindell, R. Bergholm, A. Hamsten, P. Eriksson, R.M. Fisher, M. Oresic, and H. Yki-Jarvinen Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity Diabetes 56 2007 1960 1968
82. M. Shimabukuro, M. Higa, Y.T. Zhou, M.Y. Wang, C.B. Newgard, and R.H. Unger Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression J. Biol. Chem. 273 1998 32487 32490
83. E. Boslem, G. MacIntosh, A.M. Preston, C. Bartley, A.K. Busch, M. Fuller, D.R. Laybutt, P.J. Meikle, and T.J. Biden A lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking Biochem. J. 435 2011 267 276
84. R. Veluthakal, R. Palanivel, Y. Zhao, P. McDonald, S. Gruber, and A. Kowluru Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta cell Apoptosis 10 2005 841 850
85. K. Maedler, G.A. Spinas, D. Dyntar, W. Moritz, N. Kaiser, and M.Y. Donath Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function Diabetes 50 2001 69 76
86. J.M. McGavock, I. Lingvay, I. Zib, T. Tillery, N. Salas, R. Unger, B.D. Levine, P. Raskin, R.G. Victor, and L.S. Szczepaniak Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study Circulation 116 2007 1170 1175
87. C. Christoffersen, E. Bollano, M.L. Lindegaard, E.D. Bartels, J.P. Goetze, C.B. Andersen, and L.B. Nielsen Cardiac lipid accumulation associated with diastolic dysfunction in obese mice Endocrinology 144 2003 3483 3490
88. M. Di Paola, T. Cocco, and M. Lorusso Ceramide interaction with the respiratory chain of heart mitochondria Biochemistry 39 2000 6660 6668
89. A.E. Bielawska, J.P. Shapiro, L. Jiang, H.S. Melkonyan, C. Piot, C.L. Wolfe, L.D. Tomei, Y.A. Hannun, and S.R. Umansky Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion Am. J. Pathol. 151 1997 1257 1263
90. T.S. Park, Y. Hu, H.L. Noh, K. Drosatos, K. Okajima, J. Buchanan, J. Tuinei, S. Homma, X.C. Jiang, E.D. Abel, and I.J. Goldberg Ceramide is a cardiotoxin in lipotoxic cardiomyopathy J. Lipid Res. 49 2008 2101 2112
91. R. Shibata, K. Sato, D.R. Pimentel, Y. Takemura, S. Kihara, K. Ohashi, T. Funahashi, N. Ouchi, and K. Walsh Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms Nat. Med. 11 2005 1096 1103
92. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425 432
93. R.S. Ahima, D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier, and J.S. Flier Role of leptin in the neuroendocrine response to fasting Nature 382 1996 250 252
94. M. Maffei, J. Halaas, E. Ravussin, R.E. Pratley, G.H. Lee, Y. Zhang, H. Fei, S. Kim, R. Lallone, and S. Ranganathan Leptin levels in human and rodent: measurement of plasma leptin and ob Nat. Med. 1 1995 1155 1161
95. J.L. Halaas, K.S. Gajiwala, M. Maffei, S.L. Cohen, B.T. Chait, D. Rabinowitz, R.L. Lallone, S.K. Burley, and J.M. Friedman Weight-reducing effects of the plasma protein encoded by the obese gene Science 269 1995 543 546
96. Y. Minokoshi, M.S. Haque, and T. Shimazu Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats Diabetes 48 1999 287 291
97. E. Bonzon-Kulichenko, D. Schwudke, N. Gallardo, E. Molto, T. Fernandez-Agullo, A. Shevchenko, and A. Andres Central leptin regulates total ceramide content and sterol regulatory element binding protein-1C proteolytic maturation in rat white adipose tissue Endocrinology 150 2009 169 178
98. M.J. Potthoff, S.A. Kliewer, and D.J. Mangelsdorf Endocrine fibroblast growth factors 15/19 and 21: from feast to famine Genes Dev. 26 2012 312 324
99. Y. Zhao, J.D. Dunbar, and A. Kharitonenkov FGF21 as a therapeutic reagent Adv. Exp. Med. Biol. 728 2012 214 228
100. W.L. Holland, A.C. Adams, J.T. Brozinick, H.H. Bui, Y. Miyauchi, C.M. Kusminski, S.M. Bauer, M. Wade, E. Singhal, C.C. Cheng, K. Volk, M.S. Kuo, R. Gordillo, A. Kharitonenkov, and P.E. Scherer An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice Cell Metab. 17 2013 790 797
101. P.A. Dutchak, T. Katafuchi, A.L. Bookout, J.H. Choi, R.T. Yu, D.J. Mangelsdorf, and S.A. Kliewer Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones Cell 148 2012 556 567
102. K. Sun, C.M. Kusminski, and P.E. Scherer Adipose tissue remodeling and obesity J. Clin. Invest. 121 2011 2094 2101
103. J.Y. Kim, E. van de Wall, M. Laplante, A. Azzara, M.E. Trujillo, S.M. Hofmann, T. Schraw, J.L. Durand, H. Li, G. Li, L.A. Jelicks, M.F. Mehler, D.Y. Hui, Y. Deshaies, G.I. Shulman, G.J. Schwartz, and P.E. Scherer Obesity-associated improvements in metabolic profile through expansion of adipose tissue J. Clin. Invest. 117 2007 2621 2637
104. C.M. Kusminski, W.L. Holland, K. Sun, J. Park, S.B. Spurgin, Y. Lin, G.R. Askew, J.A. Simcox, D.A. McClain, C. Li, and P.E. Scherer MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity Nat. Med. 18 2012 1539 1549